Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads

This article was originally published in The Tan Sheet

Executive Summary

An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.

You may also be interested in...



Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement

The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”

Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement

The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”

RCT Spells Requirement For Lipidryl, Shrinking Beauty Weight Loss Claims

Although FTC orders for RCTs to substantiate claims are criticized by some industry stakeholders, the agency routinely includes the burden of clinical trials in settlements with firms found to conduct false and misleading advertising for consumer health products, particularly in the weight loss area.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106572

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel